Combination Strategies in the Treatment of Multiple Myeloma

Objective
To determine and prioritize optimal combinations for the treatment of multiple myeloma, as well as identify and apply new technologies for determining and testing combinations preclinically and clinically.

Sponsors
This roundtable is made possible by the Multiple Myeloma Research Foundation (MMRF), through educational grants from Celgene Corporation, Millennium Pharmaceuticals, Inc., Keryx Biopharmaceuticals, Inc., Kosan Biosciences Incorporated, and Merck & Co., Inc.

View Agenda, Paricipant List, and Abstracts (pdf)